We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of To read the full...
By Andrea Figueras Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types. The Swiss pharmaceutical company said...
January 10, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved...
By Stephen Nakrosis LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche. Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting, who...
By Mauro Orru Roche Holding's Xolair antibody received priority review treatment from the Food and Drug Administration after a late-stage study yielded positive results that the company said...
By Sabela Ojea Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment. At 9:43 a.m. ET...
By Andrea Figueras Roche said that it has received positive long-term follow-up data and significant overall survival benefit from the Katherine study, which examines people with early-stage...
By Andrea Figueras Roche said it obtained positive results for its investigational treatment, inavolisib, as a first-line treatment for people with breast cancer. The drug, which combines...
By Helena Smolak Shares of Germany's Merck KGaA plunged after its experimental drug evobrutinib failed in two late-stage trials of patients with relapsing forms of multiple sclerosis. At 0927...
By Mauro Orru Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer. The Swiss pharmaceutical company said Tuesday...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.08 | -5.58989518947 | 37.21 | 37.27 | 35.03 | 1031375 | 35.98069641 | DR |
4 | -4.76 | -11.9328152419 | 39.89 | 40.67 | 35.03 | 1159660 | 38.59951372 | DR |
12 | -6.65 | -15.9167065582 | 41.78 | 42.43 | 35.03 | 1358162 | 39.0973737 | DR |
26 | 2.13 | 6.45454545455 | 33 | 42.43 | 31.19 | 1733717 | 37.13131885 | DR |
52 | 1.76 | 5.27419838178 | 33.37 | 42.43 | 29.2 | 2075145 | 34.52768357 | DR |
156 | -14.28 | -28.9010321797 | 49.41 | 53.86 | 27.95 | 1851740 | 38.249473 | DR |
260 | -3 | -7.86782061369 | 38.13 | 53.86 | 27.95 | 1739882 | 39.98221416 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions